AstraZeneca to Expand Oncology Portfolio with $2 Billion Fusion Pharmaceutical Acquisition
- March 22, 2024
AstraZeneca is planning to buy Fusion Pharmaceuticals, Inc. and its pipeline of next-generation radioconjugates (RCs) for $2 billion in cash upfront to expand the pharmaceutical giant’s oncology portfolio in this fast-growing space.
ARTICLE TAGS
You must be logged in to access this content.